DK2790717T3 - Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein - Google Patents

Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein Download PDF

Info

Publication number: DK2790717T3
Authority: DK; Denmark
Prior art keywords: collagen; methods; binding polypeptide; pth; pthrp receptor
Prior art date: 2011-12-14

Application number

DK12857691.5T

Other languages

English (en)

Inventor

Joshua Sakon

Ranjitha Katikaneni

Tulasi Ponnapakkam

Takaki Koide

Robert C Gensure

Sagaya Theresa Leena Philominathan

Osamu Matsushita

Nozomu Nishi

Original Assignee

Univ Arkansas

The Kitasato Inst

Montefiore Med Center

Univ Kagawa Nat Univ Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-14

Filing date

2012-12-14

Publication date

2018-07-30

2012-12-14 Application filed by Univ Arkansas, The Kitasato Inst, Montefiore Med Center, Univ Kagawa Nat Univ Corp filed Critical Univ Arkansas

2018-07-30 Application granted granted Critical

2018-07-30 Publication of DK2790717T3 publication Critical patent/DK2790717T3/da

Links

239000003814 drug Substances 0.000 title abstract 5
229940124597 therapeutic agent Drugs 0.000 title abstract 5
102100027287 Serpin H1 Human genes 0.000 title 1
108050008290 Serpin H1 Proteins 0.000 title 1
102000008186 Collagen Human genes 0.000 abstract 6
108010035532 Collagen Proteins 0.000 abstract 6
229920001436 collagen Polymers 0.000 abstract 6
238000000034 method Methods 0.000 abstract 5
229920001184 polypeptide Polymers 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
102000006461 Parathyroid Hormone Receptors Human genes 0.000 abstract 4
108010058828 Parathyroid Hormone Receptors Proteins 0.000 abstract 4
239000000203 mixture Substances 0.000 abstract 4
239000000018 receptor agonist Substances 0.000 abstract 3
229940044601 receptor agonist Drugs 0.000 abstract 3
102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 2
230000001580 bacterial effect Effects 0.000 abstract 2
239000002464 receptor antagonist Substances 0.000 abstract 2
229940044551 receptor antagonist Drugs 0.000 abstract 2
201000004384 Alopecia Diseases 0.000 abstract 1
201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
208000025645 collagenopathy Diseases 0.000 abstract 1
208000024963 hair loss Diseases 0.000 abstract 1
230000003676 hair loss Effects 0.000 abstract 1
230000003659 hair regrowth Effects 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Birds (AREA)
Wood Science & Technology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)

DK12857691.5T 2011-12-14 2012-12-14 Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein DK2790717T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161570620P	2011-12-14	2011-12-14
US201261596869P	2012-02-09	2012-02-09
PCT/US2012/069831 WO2013090770A2 (en)	2011-12-14	2012-12-14	Delivery of therapeutic agents by a collagen binding protein

Publications (1)

Publication Number	Publication Date
DK2790717T3 true DK2790717T3 (da)	2018-07-30

Family

ID=48613370

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK18173596.0T DK3391899T3 (da)	2011-12-14	2012-12-14	Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
DK12857691.5T DK2790717T3 (da)	2011-12-14	2012-12-14	Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK18173596.0T DK3391899T3 (da)	2011-12-14	2012-12-14	Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein

Country Status (7)

Country	Link
US (3)	US9579273B2 (da)
EP (4)	EP3391899B1 (da)
JP (5)	JP6366507B2 (da)
CA (2)	CA2859412C (da)
DK (2)	DK3391899T3 (da)
ES (3)	ES2975215T3 (da)
WO (1)	WO2013090770A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2155874B1 (en)	2007-04-09	2016-05-11	The Board Of Trustees Of The University Of Arkansas	Fusion proteins of collagen-binding domain and parathyroid hormone
CA2859412C (en)	2011-12-14	2021-05-25	The Board Of Trustees Of The University Of Arkansas	Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
US9526765B2 (en)	2012-02-09	2016-12-27	The Kitasato Institute	Delivery of therapeutic agents by a collagen binding protein
JP7397440B2 (ja) *	2017-02-10	2023-12-13	ザボードオブトラスティーズオブザユニバーシティオブアーカンソー	コラーゲン結合薬剤組成物およびその使用方法
GB201706781D0 (en)	2017-04-28	2017-06-14	Univ Sheffield	Parathyroid hormone fusion polypeptide
KR101964376B1 (ko) *	2017-09-29	2019-04-01	주식회사 나이벡	부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료
JP7045166B2 (ja) *	2017-11-07	2022-03-31	株式会社ニッピ	コラーゲン結合材、その製造方法、ドラッグデリバリーシステム、および担持体
US11529389B2 (en)	2018-03-09	2022-12-20	University of Pittsburgh—of the Commonwealth System of Higher Education	Delivering biological drugs to tissues
US20220363778A1 (en) *	2019-08-28	2022-11-17	The Research Foundation For The State University Of New York	Targeted delivery of tumor matrix modifying enzymes
US20240016900A1 (en) *	2022-06-27	2024-01-18	Sustain Holdings, Llc	Collagen peptide-based medicament compositions and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8516421D0 (en)	1985-06-28	1985-07-31	Biotechnology Interface Ltd	Fibronectins
DE69429337T3 (de) *	1993-04-02	2012-08-30	Anticancer Inc.	Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
ES2248853T3 (es)	1996-07-31	2006-03-16	The General Hospital Corporation	Nuevos analogos del peptido relacionado con la hormona paratiroidea.
US20100267012A1 (en) *	1997-11-04	2010-10-21	Bergeron Michel G	Highly conserved genes and their use to generate probes and primers for detection of microorganisms
US6387663B1 (en)	1998-07-31	2002-05-14	University Of Southern California	Targeting pharmaceutical agents to injured tissues
US7601685B2 (en)	1998-08-27	2009-10-13	Eidgenossische Technische Hochschule Zurich	Growth factor modified protein matrices for tissue engineering
CN1347456A (zh)	1999-02-19	2002-05-01	泰尔茂株式会社	胶原结合生理活性多肽
US20020102709A1 (en)	1999-02-19	2002-08-01	Tetsuya Ishikawa	Collagen-binding physiologically active polypeptide
US6908994B1 (en)	1999-05-10	2005-06-21	The Texas A&M University System	Collagen-binding proteins from enterococcal bacteria
US6756480B2 (en) *	2000-04-27	2004-06-29	Amgen Inc.	Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en)	2000-04-27	2005-06-09	Amgen Inc.	Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU2001278737A1 (en)	2000-08-15	2002-02-25	Terumo Kabushiki Kaisha	Collagen-binding hybrid polypeptide
JP2002058485A (ja) *	2000-08-16	2002-02-26	Terumo Corp	コラーゲン結合性を有する骨形成促進融合蛋白質
MXPA04006021A (es)	2001-12-18	2005-08-19	Eth Zuerich	Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos.
WO2004011484A2 (en)	2002-07-25	2004-02-05	The General Hospital Corporation	Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
ES2269973T3 (es)	2003-02-13	2007-04-01	Synthes Ag Chur	Mezcla inyectable para sustituir un tejido oseo.
US20040220094A1 (en)	2003-05-01	2004-11-04	Skinner Keith K.	Inverse agonist and agonist peptides that stimulate/inhibit hair growth
EP1680073B1 (en)	2003-10-21	2013-01-02	IGF Oncology, LLC	Compounds and method for treating cancer
WO2005046798A1 (en)	2003-11-12	2005-05-26	Nps Allelix Corp.	Treatment of bone loss utilizing full length parathyroid hormone
EP1557176A1 (en)	2004-01-26	2005-07-27	Ferring B.V.	Treatment of bone metastases by means of PTH receptor agonists
US8030448B2 (en) *	2004-02-16	2011-10-04	Techno Network Shikoku Co., Ltd.	Polypeptide having collagen-like structure
US20090005298A1 (en)	2004-02-27	2009-01-01	The University Of Western Ontario	Bone Sialoprotein Collagen-Binding Peptides
DK3404102T3 (da)	2004-04-21	2021-09-06	Alexion Pharma Inc	Knogletilførselskonjugater og fremgangsmåde til anvendelse heraf til målretning af proteiner mod knogle
CA2582552A1 (en)	2004-10-21	2006-05-04	Igf Oncology, Llc	Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
WO2006073711A2 (en)	2005-01-06	2006-07-13	Kuros Biosurgery Ag	Use of a matrix comprising a contrast agent in soft tissues
WO2007073661A1 (fr) *	2005-12-26	2007-07-05	Yantai Zhenghai Bio-Technology Co., Ltd.	Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee
EP2086321B1 (en) *	2006-11-16	2016-08-31	Kai Pharmaceuticals, Inc.	Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
EP1961765A1 (en) *	2006-12-08	2008-08-27	Zealand Pharma A/S	Truncated PTH peptides with a cyclic conformation
WO2008101406A1 (en) *	2007-02-14	2008-08-28	Yolare Dermaceuticals, Llc	Modified mutant collagenase and it's use in fat melting and in scar reduction
WO2008123166A1 (en) *	2007-03-20	2008-10-16	Nsk-Warner K.K.	Roller-type one-way clutch
EP2155874B1 (en) *	2007-04-09	2016-05-11	The Board Of Trustees Of The University Of Arkansas	Fusion proteins of collagen-binding domain and parathyroid hormone
EP2178905B1 (en) *	2007-07-26	2013-11-06	Allergan, Inc.	Methods of activiting clostridial toxins
US20100159564A1 (en) *	2007-11-30	2010-06-24	Dwulet Francis E	Protease resistant recombinant bacterial collagenases
JP5400336B2 (ja)	2008-08-04	2014-01-29	トヨタ紡織株式会社	表皮材の成形装置
US10545149B2 (en)	2008-10-06	2020-01-28	Morehouse School Of Medicine	Detection of HIV-related proteins in urine
JP2010172247A (ja)	2009-01-29	2010-08-12	Kitasato Institute	積層型高密度培養人工組織の製造方法及び積層型高密度培養人工組織
WO2011060431A2 (en) *	2009-11-16	2011-05-19	University Of Maryland Baltimore	Multivalent live vector vaccine against clostridium difficile-associated disease
WO2011142425A1 (ja) *	2010-05-12	2011-11-17	国立大学法人香川大学	上皮層含有組織の再生材および再生評価方法
ES2385239B1 (es) *	2010-09-30	2013-06-19	Proteos Biotech S.L.U.	Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
AU2012227790C1 (en) *	2011-03-16	2016-06-30	Meiji Seika Pharma Co., Ltd.	Probe for analyzing biological tissue and method for utilizing same
JP5512887B2 (ja)	2011-05-13	2014-06-04	学校法人北里研究所	成長因子アンカーリング型骨移植材料および成長因子アンカーリング型骨移植材料製造用キット
CA2859412C (en) *	2011-12-14	2021-05-25	The Board Of Trustees Of The University Of Arkansas	Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
HUE046160T2 (hu) *	2012-01-12	2020-02-28	Endo Global Ventures	Clostridium histolyticum enzim
US8915726B2 (en) *	2012-02-08	2014-12-23	Shining Golden Yida Welding & Cutting Machinery Manufacture Ltd.	Rotary vane air motor with improved vanes and other improvements
US9526765B2 (en) *	2012-02-09	2016-12-27	The Kitasato Institute	Delivery of therapeutic agents by a collagen binding protein
US9962428B2 (en) *	2012-12-21	2018-05-08	National University Corporation Nagoya University	Composition having tissue-repairing activity, and use therefor
WO2015048334A2 (en) *	2013-09-25	2015-04-02	Pronutria, Inc.	Edible species nutritive polypeptides and methods of production and use thereof
US9539363B2 (en) *	2014-04-24	2017-01-10	Warsaw Orthopedic, Inc.	Collagen matrix
US20180140742A1 (en) *	2014-10-16	2018-05-24	School Juridical Person Kitasato Institute	Graft material for nerve regeneration, method for producing graft material for nerve regeneration, and kit for producing graft material for nerve regeneration
EP3112474A1 (en) *	2015-06-29	2017-01-04	Evonik Degussa GmbH	Method of detecting avian necrotic enteritis
US10513696B2 (en) *	2016-05-24	2019-12-24	Hamzeh Alipour	Lucilia sericata collagenase
SI3518960T1 (sl) *	2016-09-29	2023-11-30	Ascendis Pharma Bone Diseases A/S,	Odmerni režim za PTH spojino z nadzorovanim sproščanjem
JP7397440B2 (ja) *	2017-02-10	2023-12-13	ザボードオブトラスティーズオブザユニバーシティオブアーカンソー	コラーゲン結合薬剤組成物およびその使用方法
WO2019113123A1 (en) *	2017-12-04	2019-06-13	Precithera, Inc.	TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
US10519236B2 (en) *	2018-01-23	2019-12-31	New York University	Antibodies specific to delta 1 chain of T cell receptor
US11529389B2 (en) *	2018-03-09	2022-12-20	University of Pittsburgh—of the Commonwealth System of Higher Education	Delivering biological drugs to tissues
SG11202101151SA (en) *	2018-08-14	2021-03-30	Osteoqc Inc	Pyrrolo - dipyridine compounds

2012
- 2012-12-14 CA CA2859412A patent/CA2859412C/en active Active
- 2012-12-14 EP EP18173596.0A patent/EP3391899B1/en active Active
- 2012-12-14 EP EP24153256.3A patent/EP4397755A2/en active Pending
- 2012-12-14 DK DK18173596.0T patent/DK3391899T3/da active
- 2012-12-14 ES ES20184066T patent/ES2975215T3/es active Active
- 2012-12-14 DK DK12857691.5T patent/DK2790717T3/da active
- 2012-12-14 WO PCT/US2012/069831 patent/WO2013090770A2/en active Application Filing
- 2012-12-14 EP EP20184066.7A patent/EP3808365B1/en active Active
- 2012-12-14 CA CA3113972A patent/CA3113972C/en active Active
- 2012-12-14 ES ES18173596T patent/ES2816009T3/es active Active
- 2012-12-14 JP JP2014547503A patent/JP6366507B2/ja active Active
- 2012-12-14 EP EP12857691.5A patent/EP2790717B1/en active Active
- 2012-12-14 US US14/365,226 patent/US9579273B2/en active Active
- 2012-12-14 ES ES12857691T patent/ES2695161T3/es active Active
2017
- 2017-01-17 US US15/407,589 patent/US11001820B2/en active Active
2018
- 2018-03-05 JP JP2018038513A patent/JP6697019B2/ja active Active
2019
- 2019-02-22 US US16/283,468 patent/US11279922B2/en active Active
2020
- 2020-01-06 JP JP2020000376A patent/JP2020073554A/ja active Pending
2021
- 2021-10-22 JP JP2021172953A patent/JP7327765B2/ja active Active
2023
- 2023-07-26 JP JP2023121669A patent/JP2023153154A/ja active Pending

Also Published As

Publication number	Publication date
JP2015513312A (ja)	2015-05-07
JP6697019B2 (ja)	2020-05-20
JP7327765B2 (ja)	2023-08-16
EP3808365A1 (en)	2021-04-21
EP2790717A2 (en)	2014-10-22
EP4397755A2 (en)	2024-07-10
DK3391899T3 (da)	2020-08-24
ES2816009T3 (es)	2021-03-31
WO2013090770A2 (en)	2013-06-20
JP2020073554A (ja)	2020-05-14
EP3391899B1 (en)	2020-07-15
CA2859412A1 (en)	2013-06-20
US11001820B2 (en)	2021-05-11
JP2022023162A (ja)	2022-02-07
EP2790717A4 (en)	2016-03-09
JP2023153154A (ja)	2023-10-17
JP6366507B2 (ja)	2018-08-01
WO2013090770A3 (en)	2014-12-31
US11279922B2 (en)	2022-03-22
JP2018104461A (ja)	2018-07-05
US20190249163A1 (en)	2019-08-15
ES2975215T3 (es)	2024-07-04
CA3113972C (en)	2023-08-01
EP3808365B1 (en)	2024-01-31
EP3391899A1 (en)	2018-10-24
US20170204390A1 (en)	2017-07-20
CA2859412C (en)	2021-05-25
ES2695161T3 (es)	2019-01-02
US20140377215A1 (en)	2014-12-25
CA3113972A1 (en)	2013-06-20
US9579273B2 (en)	2017-02-28
EP2790717B1 (en)	2018-05-30

Publication	Publication Date	Title
DK2790717T3 (da)	2018-07-30	Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
SG158112A1 (en)	2010-01-29	Hepatocyte growth factor (hgf) binding proteins
AU2018260809A1 (en)	2018-11-22	Compounds and uses thereof for the modulation of hemoglobin
WO2007143098A3 (en)	2008-06-12	Hepatocyte growth factor (hgf) binding proteins
AU2018260808A1 (en)	2018-11-22	Compounds and uses thereof for the modulation of hemoglobin
MX349198B (es)	2017-07-18	Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
NZ602734A (en)	2014-10-31	Therapeutic dll4 binding proteins
MX2010008206A (es)	2010-08-10	Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
PH12015500084A1 (en)	2015-03-02	Rspo3 binding agents and uses thereof
MX344559B (es)	2016-12-20	Compuestos de hormona de crecimiento humana recombinante unidos al peg.
NZ598524A (en)	2014-06-27	Therapeutic dll4 binding proteins
GB201201314D0 (en)	2012-03-07	Composition
PH12015500194A1 (en)	2015-04-20	Fusion proteins for treating a metabolic syndrome
TN2014000110A1 (en)	2015-07-01	Dual function proteins for treating metabolic disorders
MX2019000586A (es)	2021-06-15	Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
MX2015011769A (es)	2016-06-02	Compuestos y sus usos para modular la hemoglobina.
MX2015011509A (es)	2016-05-31	Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2010009743A (es)	2010-09-28	Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
EA201000559A1 (ru)	2010-10-29	Композиции и способы применения антител к склеростину
MX2010006519A (es)	2010-10-15	Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
NZ603570A (en)	2014-12-24	Biological materials related to her3
MX2013011706A (es)	2014-04-25	Proteinas novedosas de enlace a antigeno.
GEP20196969B (en)	2019-04-25	New therapeutical composition containing apomorphine as active ingredient
WO2013190567A3 (en)	2014-10-23	Composition and method for an intradermal hair growth solution
MX360157B (es)	2018-10-24	Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.